JP2020534830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534830A5 JP2020534830A5 JP2020516462A JP2020516462A JP2020534830A5 JP 2020534830 A5 JP2020534830 A5 JP 2020534830A5 JP 2020516462 A JP2020516462 A JP 2020516462A JP 2020516462 A JP2020516462 A JP 2020516462A JP 2020534830 A5 JP2020534830 A5 JP 2020534830A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 24
- 102000036639 antigens Human genes 0.000 claims 24
- 108091007433 antigens Proteins 0.000 claims 24
- 230000027455 binding Effects 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 19
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 17
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 17
- 238000000034 method Methods 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023105809A JP7737193B2 (ja) | 2017-09-21 | 2023-06-28 | 新規抗ＣＤ３ε抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/102622 | 2017-09-21 | ||
| CN2017102622 | 2017-09-21 | ||
| PCT/CN2018/106618 WO2019057099A1 (en) | 2017-09-21 | 2018-09-20 | NOVEL ANTI-CD3EPSILON ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105809A Division JP7737193B2 (ja) | 2017-09-21 | 2023-06-28 | 新規抗ＣＤ３ε抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534830A JP2020534830A (ja) | 2020-12-03 |
| JP2020534830A5 true JP2020534830A5 (OSRAM) | 2021-10-28 |
| JP7305624B2 JP7305624B2 (ja) | 2023-07-10 |
Family
ID=65811028
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516462A Active JP7305624B2 (ja) | 2017-09-21 | 2018-09-20 | 新規抗ＣＤ３ε抗体 |
| JP2023105809A Active JP7737193B2 (ja) | 2017-09-21 | 2023-06-28 | 新規抗ＣＤ３ε抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105809A Active JP7737193B2 (ja) | 2017-09-21 | 2023-06-28 | 新規抗ＣＤ３ε抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11440962B2 (OSRAM) |
| EP (1) | EP3684806A4 (OSRAM) |
| JP (2) | JP7305624B2 (OSRAM) |
| KR (2) | KR20250046337A (OSRAM) |
| CN (2) | CN111108119B (OSRAM) |
| AU (2) | AU2018336519B2 (OSRAM) |
| BR (1) | BR112020004992A2 (OSRAM) |
| CA (1) | CA3074130A1 (OSRAM) |
| EA (1) | EA202090800A1 (OSRAM) |
| IL (1) | IL273393A (OSRAM) |
| MX (1) | MX2020003087A (OSRAM) |
| MY (1) | MY199530A (OSRAM) |
| PH (1) | PH12020550078A1 (OSRAM) |
| SA (2) | SA523440043B1 (OSRAM) |
| SG (1) | SG11202001358RA (OSRAM) |
| TW (2) | TWI879275B (OSRAM) |
| WO (1) | WO2019057099A1 (OSRAM) |
| ZA (1) | ZA202001314B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020005675A2 (pt) | 2017-09-22 | 2020-10-20 | WuXi Biologics Ireland Limited | novos complexos de polipeptideo cd3/cd19 biespecíficos |
| PH12020550112A1 (en) | 2017-09-22 | 2020-10-26 | Wuxi Biologics Ireland Ltd | Novel bispecific polypeptide complexes |
| US20230002487A1 (en) * | 2019-06-07 | 2023-01-05 | Adimab, Llc | High affinity anti-cd3 antibodies, and methods for their generation and use |
| US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
| JP7765397B2 (ja) | 2020-03-12 | 2025-11-06 | イミューン－オーエヌシー セラピューティクス，インコーポレーテッド | 新規抗ｌｉｌｒｂ４抗体および派生産物 |
| CR20220594A (es) | 2020-05-27 | 2023-01-17 | Janssen Biotech Inc | Proteins comprising cd3 antigen binding domains and uses thereof |
| WO2022022464A1 (zh) * | 2020-07-27 | 2022-02-03 | 正大天晴药业集团股份有限公司 | 新型双特异性抗cd3/cd20多肽复合物配制剂 |
| WO2022204316A2 (en) * | 2021-03-24 | 2022-09-29 | Twist Bioscience Corporation | Variant nucleic acid libraries for cd3 |
| US11795224B2 (en) * | 2021-03-24 | 2023-10-24 | China Medical University Hospital | Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN115558023A (zh) * | 2021-07-02 | 2023-01-03 | 安源医药科技（上海）有限公司 | 抗cd3抗体及其用途 |
| CN118922442A (zh) * | 2022-03-14 | 2024-11-08 | 成都盛世君联生物技术有限公司 | 一种抗cd3抗体及其制备方法和用途 |
| CN115286715B (zh) * | 2022-05-18 | 2023-05-23 | 上海百英生物科技股份有限公司 | 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法 |
| WO2024092038A2 (en) * | 2022-10-25 | 2024-05-02 | Ablexis, Llc | Anti-cd3 antibodies |
| EP4623007A1 (en) | 2022-11-24 | 2025-10-01 | WuXi Biologics Ireland Limited | Psma antibodies and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020142000A1 (en) * | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| CN1169953C (zh) * | 1999-11-30 | 2004-10-06 | 中国医学科学院中国协和医科大学血液学研究所血液病医院 | 抗cd3单克隆抗体重链和轻链可变区基因及其应用 |
| UA94211C2 (ru) * | 2004-06-03 | 2011-04-26 | Новиммюн С.А. | Выделенное полностью человеческое моноклональное cd3 антитело |
| EP3770174A1 (en) * | 2005-10-11 | 2021-01-27 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| RU2561457C2 (ru) | 2007-04-03 | 2015-08-27 | Эмджен Рисерч (Мьюник) Гмбх | Cd3-эпсилон-связывающий домен с межвидовой специфичностью |
| WO2008119566A2 (en) * | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific bispecific binders |
| DK2356153T3 (en) | 2008-10-01 | 2016-07-04 | Amgen Res Munich Gmbh | Bispecific single CHAIN PSMAXCD3 ANTIBODY THAT ARE SPECIFICALLY TO ALL SPECIES |
| WO2011109588A1 (en) * | 2010-03-03 | 2011-09-09 | Health Research Inc. | Novel cd3 epsilon immunogens and antibodies |
| CN104098698B (zh) * | 2013-04-08 | 2019-04-05 | 中国人民解放军第二军医大学 | 一种抗cd3抗体及其制法和应用 |
| SG11201509361TA (en) * | 2013-05-28 | 2015-12-30 | Numab Ag | Novel antibodies |
| PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
| BR112016022819A2 (pt) | 2014-05-28 | 2018-01-16 | Hoffmann La Roche | uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo |
| JP6708635B2 (ja) * | 2014-10-09 | 2020-06-10 | エンクマフ エスアーエールエル | ＣＤ３εおよびＲＯＲ１に対する二特異性抗体 |
| CA2974453A1 (en) * | 2015-01-23 | 2016-07-28 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
-
2018
- 2018-09-20 CA CA3074130A patent/CA3074130A1/en active Pending
- 2018-09-20 MY MYPI2020001058A patent/MY199530A/en unknown
- 2018-09-20 WO PCT/CN2018/106618 patent/WO2019057099A1/en not_active Ceased
- 2018-09-20 US US16/649,149 patent/US11440962B2/en active Active
- 2018-09-20 PH PH1/2020/550078A patent/PH12020550078A1/en unknown
- 2018-09-20 TW TW112146907A patent/TWI879275B/zh active
- 2018-09-20 CN CN201880056557.3A patent/CN111108119B/zh active Active
- 2018-09-20 SG SG11202001358RA patent/SG11202001358RA/en unknown
- 2018-09-20 KR KR1020257008876A patent/KR20250046337A/ko active Pending
- 2018-09-20 BR BR112020004992-1A patent/BR112020004992A2/pt unknown
- 2018-09-20 KR KR1020207011016A patent/KR102785140B1/ko active Active
- 2018-09-20 EA EA202090800A patent/EA202090800A1/ru unknown
- 2018-09-20 JP JP2020516462A patent/JP7305624B2/ja active Active
- 2018-09-20 TW TW107133192A patent/TWI820041B/zh active
- 2018-09-20 EP EP18859373.5A patent/EP3684806A4/en active Pending
- 2018-09-20 CN CN202211326811.1A patent/CN115991777A/zh active Pending
- 2018-09-20 MX MX2020003087A patent/MX2020003087A/es unknown
- 2018-09-20 AU AU2018336519A patent/AU2018336519B2/en active Active
-
2020
- 2020-02-28 ZA ZA2020/01314A patent/ZA202001314B/en unknown
- 2020-03-18 IL IL273393A patent/IL273393A/en unknown
- 2020-03-19 SA SA523440043A patent/SA523440043B1/ar unknown
- 2020-03-19 SA SA520411577A patent/SA520411577B1/ar unknown
-
2022
- 2022-08-02 US US17/816,732 patent/US12485298B2/en active Active
-
2023
- 2023-06-28 JP JP2023105809A patent/JP7737193B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201457A patent/AU2025201457A1/en active Pending